ArticleTuberculosis and respiratory diseases2026
Objective Assessment of the Cough: Listening to the Patient's Voice. A Narrative Review.
Article in Tuberculosis and respiratory diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Innovative Tools and Perspectives in Cough Management: Cancer and Cough.Tuberculosis and respiratory diseases · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite its prevalence-affecting up to 10% of adults worldwide-objective measurement of the cough-one of the most common yet least quantifiable respiratory symptoms-remains challenging. Conventional descriptors, such as 'frequent' or 'severe,' are inherently subjective and poorly reproducible, limiting clinical interpretation and standardization. Over the past five decades, technological advances have transformed cough assessment from manual counting and provocation testing to automated acoustic monitoring and neurophysiologic imaging. Modern validated systems, such as the Leicester cough monitor and VitaloJAK Cough monitoring system, provide reproducible measures of cough frequency, now accepted as regulatory trial endpoints. In contrast, cough intensity remains difficult to capture objectively. While physiologic tools that include peak cough flow, esophageal manometry, and electromyography provide mechanistic insights, they are invasive, and impractical for real-world use. Acoustic amplitude serves as a promising noninvasive surrogate, but suffers from ambient noise interference and lack of cross-device calibration. Functional magnetic resonance imaging and experimental brain positron emission tomography have further revealed cortical and subcortical dysregulation underlying cough hypersensitivity, reframing the chronic cough as a disorder of aberrant sensory processing. However, these approaches remain research tools, constrained by cost, accessibility, and limited validation. The future of cough assessment lies in integrated, multimodal systems that combine physioclassilogic, acoustic, and neuroimaging signals through AI-based analytics. Such approaches could transform the cough into a measurable digital biomarker-an objective 'fifth vital sign.' Realizing this vision will require collaborative efforts among clinicians, engineers, and policymakers to ensure validation, standardization, and clinical applicability.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.